tiprankstipranks
Emergent BioSolutions reports Q4 EPS (31c), consensus 4c
The Fly

Emergent BioSolutions reports Q4 EPS (31c), consensus 4c

Reports Q4 revenue $330.7M, consensus $296.6M. "Our 2022 performance reflects the transition the company is undergoing and, together with our 2023 forecast, stands as a baseline from which we will grow post-pandemic," said Robert G. Kramer, president and CEO of Emergent BioSolutions. "Moving forward, our strategy will continue to put patients and customers first and support governments and their public health preparedness and response capabilities while returning Emergent to sustainable long-term growth and profitability."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on EBS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles